Lilly stops mid-stage Alzheimer's drug study (Update)

Eli Lilly and Co. said Thursday that it stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers.

The company stopped testing LY2886721 because of abnormal results in liver biochemical tests. Lilly says the results were found as part of routine monitoring and it will continue to monitor all patients.

The Indianapolis company will evaluate data from the trial before deciding on the next steps for the drug. Lilly says it may continue development of similar drugs. Lilly will take a charge related to stopping the trial, but it won't affect its full-year guidance.

About 35 million people worldwide have dementia. Alzheimer's is the most common type and there are around 5 million patients in the U.S. Approved drugs like Aricept and Namenda temporarily ease symptoms, but there is no cure.

The company is also running late-stage studies on the drug solanezumab as a treatment for Alzheimer's disease. Solanezumab targets beta-amyloid, the sticky plaque that gums up the brains of patients with the disease.

In August 2010 Lilly ended a late-stage trial of the Alzheimer's drug semagacestat, which was more like LY2886721 than solanezumab. Both drugs target types of an enzyme called secretase.

Eli Lilly shares rose 7 cents to close at $51.85. They fell 26 cents to $51.59 in after-hours trading.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Lilly plans another study for Alzheimer's drug (Update)

Dec 12, 2012

Eli Lilly's experimental Alzheimer's drug has flashed potential to help with mild cases of the disease, but patients and doctors will have to wait a few more years to learn whether regulators will allow the drugmaker to sell ...

Eli Lilly 2013 profit forecast tops expectations

Jan 04, 2013

(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.

Eli Lilly halts development of Alzheimer's drug

Aug 17, 2010

(AP) -- Eli Lilly and Co. has stopped developing a potential Alzheimer's disease treatment at a time when the drugmaker is searching wide and far for new drugs to fill a large revenue hole that will form starting next year.

Lilly, Boehringer collaborate on diabetes drugs

Jan 11, 2011

(AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.